The Efficacy of Sandostatin (Long Acting Release) on Acromegalic Patients: A Study from Northwest Iran
Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 3
Abstract
ABSTRACT Introduction: Acromegaly is a clinical syndrome resulting from excessive secretion of growth hormone with the approximate prevalence of six cases per million. Somatostatin agonists are the only drug approved which can actually control, to some extent, the secretion of growth hormone after surgery. Short-acting analogues of these compounds should be taken three times a day which is very undesirable. In contrast, long-acting analogues of somatostatin have the market availability for more than one decade, but Iranian physicians have the drug accessibility only within the last few years. Aim: To determine the effects of long-acting analogue octreotide (Sandostatin Long Acting Release (LAR) on the level of Growth Hormone (GH), Insulin-like Growth Factor 1 (IGF-1) and clinical symptoms in patients with acromegaly in the northwest of Iran. Materials and Methods: The level of GH, IGF-1 and clinical symptoms were evaluated after long-acting analogue Sandostatin LAR administration in 40 acromegalic patients with no surgical history or any remarkable improvement in clinical features and IGF-1/GH levels after surgery, referred to outpatient endocrinology sections, Tabriz University of Medical Sciences were included. The serum level of GH and IGF-1 were evaluated using electro-chemiluminescence system before and after 3, 6 and 12-months of drug administration. Repeated measure test was used for statistical analysis. p<0.05 was considered as statistically significant. Results: Use of Sandostatin LAR showed 72.5% and 27.5% absolute and partial recovery, respectively. Mean level of IGF-1 before and after 3, 6 and 12-months treatment were 654.17±199.12, 423.95±228.94, 356.22±169.53, 296.25±110.6 μg/L, respectively, (p<0.001). Additionally, Mean GH level before and after 3, 6 and 12-months treatment were 31.71±3.03, 10.31±5.23, 7.28±3.11 and 6.77±4.38 μg/L, respectively, (p<0.001). Conclusion: Sandostatin LAR treatment may be an effective and proper method for treatment of GH producing adenoma in patients who are not good candidates for surgery or having high GH/ IGF-1 levels after surgery.
Authors and Affiliations
Akbar-Ali Asgarzadeh, Farzad Najafipour, Majid Mobasseri, Seyyed Mehdi Mirtajaddini, Shabnam Rashidi-Rad
Keywords
Related Articles
- EP ID EP582765
- DOI 10.7860/JCDR/2019/37567.12647
- Views 124
- Downloads 0
Incontinence Impact Questionnaire (IIQ-7) and Urogenital Distress Inventory (UDI-6): Translation and Psychometric Validation of the Iranian Version
ABSTRACT Introduction: Urinary incontinence is a common health, physical, and social problem in the world. There is an urgent need of effective questionnaires for its evaluation in Iranian women. Aim: The present study a...
Variation in the Branching Pattern of Third Part of Axillary Artery- A Case Report
Anatomical variation of the branching pattern of axillary artery is very common. The knowledge of this variation is often useful during different surgical and interventional procedures. Variations include typically of La...
Case Report of Streptococcus constellatus Bacteremia in an 11-Month-old Child-clinical and Microbiological Aspects
ABSTRACT Streptococcus constellatus (S.constellatus), normal commensal bacteria of the human oral cavity is known to be associated with abscess formation and/or bacteremias. This is an infrequently isolated organism from...
Management of Severely Dilacerated Mandibular Third Molar
Images in Medicine
Group-based Asynchronous E-learning Incorporating Revised Bloom’s Taxonomy: An Innovative Approach
ABSTRACT Introduction: Faculty development programs like Foundation for Adavancement of International Medical Education and Research (FAIMER) have integral mentoring learning web sessions, a type of group based asynchron...